12:00 AM
 | 
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Velcade bortezomib regulatory update

EMA said Johnson & Johnson's Janssen-Cilag International N.V. subsidiary withdrew an application to extend the label for Velcade bortezomib to include use in combination with rituximab to treat relapsed follicular non-Hodgkin's lymphoma (NHL). According to the agency, the subsidiary said it...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >